Introduction: Antiretroviral therapy plays a major role in reducing the impact of Human Immunodeficiency Virus/Acquired Immune Disease
Introduction
Globally, over 34 million people were infected with Human Immunodeficiency Virus (HIV) by the end of 2010 [1] . Ninety percent of them were from resource-limited settings, where there is shortage of Antiretroviral Therapy (ART) [2] . With increasing evidence that treatment programs in resource-limited settings can achieve treatment outcomes comparable to those of developed countries [3] [4] [5] [6] [7] , most countries in sub-Saharan Africa have implemented policies to increase access to ART [8] . The aim of ART is to suppress HIV replication to below the limit of detection. ART eventually provides the greatest potential for immune reconstitution and minimizes the risk of treatment failure, which arises as a combination of factors, such as bad adherence, interruption of treatment due to drug toxicity, and the emergence of resistance mutations [9, 10] .
The first HIV case in Kenya was identified in 1984. Since then, the HIV and Acquired Immune Disease Syndrome (AIDS) epidemic kept rising and remained relatively steady after 2003 with a prevalence of 6.7% among individuals aged 15-49 years (4.6% in men and 8.7% in women). By the end of 2010, it was estimated that 6.3% of Kenyans aged 15-64 years were infected. To improve the life of HIV and Acquired patients and reduce the HIV and AIDS-related morbidity and mortality, the Kenyan government significantly increased access to ART since 2003 [11] . With this increase in ART coverage, the danger of increased drug-resistant strains among drug-naive patients became real. Furthermore, stigma and social backgrounds among the infected population has affected access to ART and compliance, resulting in an accelerated emergence of drugresistant mutants, especially among those on suboptimal therapy. As in many resource-limited settings, antiretroviral drugs are limited in Kenya and only those meeting some criteria can receive treatment. There is a concern that antiretroviral drug resistance among those on treatment would spread to those acquiring new infections (who may not access treatment) and compromise the current regimens thereby giving rise to early treatment failure among those on ART. This study was carried out with the aim of establishing the prevalence of drug resistance mutations among HIV antiretroviral drugs are limited in Kenya and only those meeting some criteria can receive treatment. There is a concern that antiretroviral drug resistance among those on treatment would spread to those acquiring new infections (who may not access treatment) and compromise the current regimens thereby giving rise to early treatment failure among those on ART. This study was carried out with the aim of establishing the prevalence of drug resistance mutations among HIV-1 infected patients seeking care and treatment from an established government comprehensive care center of Kenyatta National hospital in 2009. This data would assist in better care and service provision to patients so as to improve HIV prevention initiatives for targeted resource allocation and service delivery among the infected.
Methods

Study design, subjects and antiretroviral drugs
This was a cross sectional study involving adult patients attending the comprehensive care clinic of Kenyatta national hospital, Kenya in 2009. Demographic data, such as age and gender were obtained through individualized interview. After informed consent and ethical clearance from the Kenyatta Hospital ethical committee, blood samples were collected. The patients were adults on first line antiretroviral medication for at least six months. Those who did not consent were excluded from the study as well as those on 2 nd line therapy. First-line antiretroviral drugs consisted of 2 nucleoside reverse transcriptase inhibitors, NRTIs mostly zidovudine (AZT) or tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC)] and 1 non-nucleoside reverse transcriptase inhibitor, NNRTI mostly nevirapine (NVP) or efavirenz (EFV)] as stipulated in the world health organization (WHO) guidelines [12] .
CD4+ T-cell counts
CD4+T-cell counts of peripheral blood were determined using the FACSCOUNT (Becton-Dickinson, Beiersdorf, Germany).
HIV-1 genotyping and drug resistance analysis
HIV-1 RNA was extracted from 100 µl of plasma using SMITEST EX-R and D (Genome Science Laboratories, Fukushima, Japan) according to the manufacturer's instructions. The HIV-1 reverse transcriptase (RT) gene was amplified by both one step RT polymerase chain reaction (PCR) and nested PCR as previously described [13] [14] [15] [16] . The pol-RT nucleotide sequences were translated into the corresponding amino acids and analyzed for previously reported drug resistance-associated mutations using the Stanford University HIVdb sequence analysis program [17] . The REGA HIV-1 subtyping tool [18] on the Stanford database was used to determine the HIV-1 subtype of each patient sample based on RT sequences. Generated sequences were aligned using ClustalW and phylogenetic trees viewed using FigTree [19] . Demographic, and immunologic parameters were analyzed using the student's t test to determine significance (with p value of <0.05).
Results
Patient characteristics
Between February and October 2009, 65 patient samples were collected. Of these 39 were from female and 26 from male patients. The mean age was 43 years (42 years for females (SD, 9.67) and 45 years (SD, 8.93) for males). Though males seemed to be older than females, this was not statistically significant (p = 0.2). The average duration on ART was 8 years (8.2 years for females and 7.7 years for males). Median baseline CD4 and viral loads were very low and high for females and males, respectively (Table 1) .
Antiretroviral therapy regimens
The patients were in conventional first line ART as stipulated in Kenyan ART guidelines. However, 21 patients were deemed to be clinically failing their current ART regimens. Most patients were on AZT/3TC/NVP combination at the time of this analysis before changing to AZT/3TC/LPV in their subsequent regimens.
HIV-1 Drug resistance mutations
Major NRTI mutations were detected in 11 patient samples, which included M184V (n=6), M41L (n=3), D67N (n=2), K219Q (n=3) and T215F (n=2). Major NNRTI mutations were detected in 14 patient samples. They included K103N (n=10), G190A (n=1), Y181C (n=1) and Y188L (n=1) ( Table 2 ). The prevalence of drug resistance mutations in these treatment-experienced patients was estimated to be 26%.
HIV-1 Subtypes
The generated HIV-1 RT sequences, after aligning with reference sequences from the Los Alamos HIV database (using ClustalW Figure 1) .
Discussion
In the current study, we analyzed samples from 65 HIV-1 infected patients who were on first-line ART at Kenyatta national hospital comprehensive care clinic for at least eight years. It was shown that the most prevalent HIV-1 subtype among the patients was A1, followed by D and C. As observed from boot scan values in the REGA system, most of these subtypes were pure, representing homogenous strains that are yet to develop recombination (as is the nature of HIV). These findings are in agreement with previous findings in Kenya where subtype A has consistently been reported to be the most prevalent [20, 21] .
The prevalence of drug resistance (any major mutation) was estimated to be 23.1% (15/65) among the studied population. This was higher compared to another finding among HIV infected Kenyan Injecting Drug Users where resistance was estimated to be 13.8% [22] . This difference may be attributable to different study populations. The most prevalent NRTI drug resistant mutation was M184V that has been associated with use of lamivudine. Lamivudine forms the backbone of first line ART in Kenya. The most prevalent NNRTI mutation that was detected in the studied population was K103N, which is associated with the use of Nevirapine -also a major component of first line regimens in Kenya. Among the studied patients, follow up was inconsistent for the duration of ART. This translated into missed evaluations of both virologic (viral load) and immunologic (CD4+ counts) parameters that would be used to inform regimen change. As such this might have contributed to emergence of drug resistance. Furthermore, no baseline drug resistance mutation was done before initiation of ART; hence we could not ascertain whether the mutations detected were acquired or transmitted. Similarly, no virologic (viral load) and immunologic (CD4+ counts) data was available at the time of this analysis hence we could not tell which patients were failing treatment in order to advice on regimen change.
In this study, we did bulk sequencing using plasma RNA. However, the limitation of bulk sequencing is that it compromises the detection of minor population of HIV-1 drug-resistant variants, which may exist in low copy numbers due to exposure to ART [23] . Under such circumstances, detection of minor viral variants using more sensitive methods, such as pyrosequencing and clonal or deep sequencing, would be more ideal [24] . Furthermore, our study focused on the HIV-1 RT region only, which is the target of first line drugs. Neither did we do for the protease region (target for second line drugs). This may have underestimated the prevalence of drug resistance in this setting given that baseline drug resistance (both transmitted and acquired) was not done.
Conclusion
Overall prevalence of drug resistance mutations among CCC patients in KNH in 2009 was 23.1%. This study forms a basis upon which future ART would largely depend in establishing trends so as to guide and inform the establishment of proper laboratory infrastructure to monitor treatment as well as regular appraisals of available regimens.
What is known about this topic
 Drug resistance is a major impediment to the success of ART in resource limited settings;
 Continued research/surveillance of such is of critical importance to the success of available regimens due to high possibilities of transmitted as well as acquired drug resistance.
What this study adds
 Information gathered from this study forms a vital component of existing literature on HIV Drug Resistance;
 This information may be valuable when administering regimens that have had a history of either treatment success or drug resistance-associated complications.
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